MVASI vs ROZLYTREK

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 18, 2026·How we rate

Possible drug interaction. MVASI and ROZLYTREK are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	MVASI	ROZLYTREK
Rating	72/100	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	BEVACIZUMAB-AWWB	ENTRECTINIB
Manufacturer	Amgen Inc	Genentech Inc
Dosage forms	Injectable	Capsule, Oral pellets
Drug class	—	—
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms	Non-Small-Cell Lung Carcinoma

mvasi rozlytrek

Rating

72/100

70/100

Pharmacy pays

—

Type

Active ingredient

BEVACIZUMAB-AWWB

ENTRECTINIB

Manufacturer

Amgen Inc

Genentech Inc

Dosage forms

Injectable

Capsule, Oral pellets

Drug class

—

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms

Non-Small-Cell Lung Carcinoma

Frequently asked questions

Which is better-rated, Mvasi or Rozlytrek?

By our independent rating, Mvasi scores higher — 3.6 vs 3.5 out of 5 for Rozlytrek. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Mvasi and Rozlytrek?

Mvasi contains Bevacizumab-Awwb, while Rozlytrek contains Entrectinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.